GlaxoSmithKline scores a win in Zofran case after FDA repeatedly said pregnancy risk data did not require label changes
GSK did sufficiently warn the FDA regarding birth defects tied to its nausea drug Zofran (ondansetron), and because the FDA decided not to update the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
